Drug Profile
Research programme: viral protein inhibitors - Intervir Therapeutics
Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer Intervir Therapeutics
- Class Small molecules
- Mechanism of Action Viral protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ebola virus infections; Influenza A virus infections; Junin virus infections; Lassa fever; Marburg virus disease; Rabies
Most Recent Events
- 28 May 2019 No recent reports of development identified for research development in Ebola-virus-infections in USA (Parenteral)
- 28 May 2019 No recent reports of development identified for research development in Influenza-A-virus-infections in USA (Parenteral)
- 28 May 2019 No recent reports of development identified for research development in Junin-virus-infections in USA (Parenteral)